In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Devices for severe heart failure

ESC Congress 2010

Heart Failure (HF)


Dr. Masip discussed the role of non invasive ventilation in patients with advanced and decompensated heart failure (HF). He showed that both continuous positive airway pressure ventilation (C-PAP) and non-invasive positive pressure ventilation (NIPPV) improve outcomes in patients receiving this treatment. However, there is no clear advantage to either of these modalities over the other. The key issue is to initiate treatment early, to optimise benefits.

Dr. Mebazaa presented key differences between hemodialysis and ultrafiltration in patients with HF. The use of ultrafiltration is promising in this patient population, but future studies are needed to better identify the patients most likely to benefit from this therapy. Dr. Nanas outlined the beneficial effects of the early use of intra-aortic balloon pump in patients with cardiogenic shock. Unstable patients with cardiogenic shock caused by ischemic heart disease showed significantly greater benefits when treatment was initiated prior to the intervention.

Dr. Mohr presented an elegant overview of the role of LV assist devices in advanced HF. Significant progress has been made in this field. Newer devices including those providing partial support are promising.

Finally, Dr. Abraham presented the potential clinical utilities of implantable monitoring devices. Data from the FAST, HOMEOSTASIS and CHAMPION trials showed significant benefits in patients with severe heart failure using these devices. For example, in CHAMPION, a 38% reduction in hospitalisations for HF was reported. Additional data are needed to better select the populations most likely to benefit from these devices.

References


172

SessionTitle:

Devices for severe heart failure

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.